PatientsHCP
This site is for US Health Care Professionals only.
Byron Homepage Hero Image

In most patients with HF, help HEART FAILURE MEET HEART SUCCESS1

Start ENTRESTO® to help reduce the risk of CV death and HF hospitalization

Results for HFrEFResults for HFpEF with LVEF ≤60%*

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Starting your patients on ENTRESTO

SEE DOSING

Discover support and resources to help your patients start on ENTRESTO

GET SUPPORT & RESOURCES

Inflation Reduction Act (IRA) – Maximum Fair Price (MFP) for ENTRESTO effective January 1, 2026

For more information about the ENTRESTO MFP effectuation process, or online platform for MFP claims adjudication, please visit http://mfp.beaconchannelmanagement.com ↗.

Definitions
ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin II receptor blocker; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFSA, Heart Failure Society of America; LAE, left atrial enlargement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; RASi, renin-angiotensin system inhibitor.

References
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.